Clinicians prescribe cephalexin across diverse outpatient scenarios where susceptible pathogens dominate clinical presentations. Bacterial skin infections represent the most frequent indication. Conditions such as cellulitis, impetigo, folliculitis, and wound infections respond rapidly when staphylococcal or streptococcal bacteria are the primary drivers. The drug achieves high concentrations in epidermal tissues, halting superficial spreading within 48 to 72 hours of initial administration.
Uncomplicated urinary tract infections make up another primary clinical front. Because the kidneys filter cephalexin rapidly, the active drug concentrates directly in bladder urine. Outpatient clinics routinely utilize cephalexin to treat acute cystitis, particularly in pregnant patients where other common agents, such as fluoroquinolones or trimethoprim-sulfamethoxazole, present contraindications or fetal toxicity risks.
Physicians also rely on cephalexin for targeted strep throat treatment when patients cannot tolerate front-line penicillin therapies. Beyond pharyngitis, the drug treats selected upper respiratory tract infections, otitis media in pediatric populations, and complex bone and joint infections like osteomyelitis. In chronic orthopedic scenarios, doctors frequently pair high-dose oral regimens with surgical debridement, maintaining therapy over several weeks to eradicate persistent staphylococcal colonies embedded in cortical bone.
